This text is a result of machine translation.
IntoCare Zhang Hui: Ingenuity Forges Quality, Continuous Improvement Safeguards Lives
In 2024, nearly all medical enterprises are exploring overseas markets. This trend is driven by an anti-corruption wave within the medical industry, the demand for financing and initial public offerings, as well as challenges such as excess production capacity. Presently, venturing abroad has become an essential developmental path for medical device enterprises. Successfully entering foreign markets is not only a crucial means for the medical industry to achieve a second grow
May 09, 2024 12:18 PM
Clock in Beijing McDonald's: McDonald's China launched a series of Spring Festival themed activities
Breeding stocks continued to strengthen and aonong biology rose by the limit
Alphamab Licenses Cancer Drug to Pathos AI in Deal Worth More Than US$2.2 Billion
Alphamab Oncology (康宁杰瑞生物制药) has licensed the overseas rights to its experimental cancer drug JSKN016 to US-based Pathos AI in a deal potentially worth more than US$2.2 billion, marking another major overseas licensing agreement for China’s rapidly expanding innovative-drug sector.
Aug 06, 2026 05:41 PM
Mabwell Signs GCC Licensing Deal with Saudi Arabia’s SVAX for Aflibercept Biosimilar
Mabwell (Shanghai) Bioscience Co., Ltd.(迈威(上海)生物科技股份有限公司)has entered into a licensing agreement with Saudi Arabian biopharmaceutical company SVAX Inc. covering its aflibercept biosimilar, 9MW0813, in the Gulf Cooperation Council market.
Jul 31, 2026 03:00 PM
Tencent launches new brand of games
Beida pharmaceutical: 4510000 shares pledged by Kaiming investment
TECO shares: obtained an invention patent certificate
Insilico Medicine (英矽智能) Signs Strategic Drug Discovery Partnership with Takeda (武田制药), Deal Worth Up to US$600 Million
Chinese AI drug discovery company Insilico Medicine (英矽智能) has signed a global strategic collaboration with Japanese pharmaceutical company Takeda (武田制药), with the total potential deal value reaching up to US$600 million. Announced in early July, the agreement marks another milestone in the international commercialization of China's AI-powered drug discovery technologies through collaboration with a leading multinational pharmaceutical company.
Jul 16, 2026 02:33 PM
Bandung special assistant responded: the company can not intervene in the personal debt disputes between dormant shareholders and prominent shareholders, but can only promote them laterally
Guangxi plans to divide real estate enterprises into four credit grades and implement "red blacklist" management
Wan Hongjian: Shuanghui lost more than 800 million yuan due to Bandung's "illegal related party transactions"
Beyond Capital: Why Europe Needs Industrial Partners, Not Just Investors
Aug 04, 2026 11:21 AM
A Small Aircraft, a Bigger Bet: How China's Worthy Aero Plans to Scale Up
Jul 31, 2026 02:44 PM